Our mission is to develop best in class, clinically supported healthcare and nutritional products for consumers and partners worldwide

For over 17 years, we have researched the human microbiome, to develop a unique portfolio of native human strains that has been recognized by leading scientists and clinicians. 

Through our expertise in discovery and development, we provide probiotics that

  • unlock the potential of the gut-brain axis

  • improve infant nutrition, during pregnancy and childhood

  • improve metabolic health

  • stimulate anti-inflammatory or anti-viral activity

  • add all areas partners might be researching where we have credible strain


35624 Culture

35624®, a Bifidobacterium longum culture, now the No 1 recommended probiotic by US Gastroenterologists and Doctors in the US*. 35624 has been shown in 2 landmark clinical trials** and over XX publications, to reduce any and all of the following symptoms:

Bloating & gas

Abdominal pain

Unpredictable diarrhoea and constip ation

It is currently commercialised globally as a food supplement.

Learn more about 35624


1714® Culture

1714-Serenitas(TM), one of the first probiotics clinically proven to reduce levels of the stress hormone, cortisol.***. With growing interest in the potential of the gut-brain axis and 'psychobiotics', the 1714 culture has demonstrated ground breaking clinical activity (ENCK?) and safety.

Add text on continuous research/upcoming data

It is currently commercialised as a food supplement in Europe, Zenflore®.


*Among gastroenterologists who recommended a brand of probiotic in AlphaImpactRx 2008–2017 surveys. Among doctors who recommended a brand of probiotic in AlphaImpactRx 2017 survey.

**Whorwell, O'Mahony - ADDREF

***Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognitive in healthy volunteers. Allen et al., Transl Psychiatry, 2016